What is Collidion?
Collidion, Inc., established in 2015, is a healthcare innovation company focused on addressing critical unmet needs globally. The company develops and commercializes novel anti-infective technologies, providing capital and operational support to its subsidiaries, Spectrum Antimicrobials and Plex Pharmaceuticals. These subsidiaries are dedicated to enhancing patient care through advanced disinfection, sterilization, and treatments for complex diseases such as Parkinson's and glioblastoma. Collidion's strategic approach involves fostering innovation and forging global partnerships to advance healthcare technologies.
How much funding has Collidion raised?
Collidion has raised a total of $230K across 1 funding round:
Debt
$230K
Debt (2021): $230K with participation from PPP
What's next for Collidion?
With its recent large-scale late-stage funding, Collidion is poised to accelerate its development pipeline and expand the commercial reach of its subsidiaries. The strategic investment suggests confidence from backers in the company's ability to scale its operations and penetrate key markets. Future initiatives will likely focus on advancing clinical trials, securing regulatory approvals, and establishing broader distribution networks for its anti-infective solutions and therapeutic technologies. This capital infusion is critical for navigating the complexities of late-stage development and achieving its mission of enhancing global health.
See full Collidion company page
